ITP Clinical Trial - Anti-BCMA CAR T-Cell Therapy for R/R ITP

Status Recruiting

Clinical Trial Summary

This is a prospective, single-center, open-label, single-arm study, to evaluate the efficacy and safety of Anti-BCMA chimeric antigen receptor T cell therapy（BCMA CAR-T）for patients with relapse/refractory Immune thrombocytopenia(R/R ITP).

Clinical Trial Description

Immune thrombocytopenia (ITP) is a disorder that can lead to easy or excessive bruising and bleeding. Approximately two-thirds of patients achieve remission after/during first-line therapies. However, the other part of patients could not achieve durable remission or even refractory to initial treatments. Those cases, known as relapse/refractory Immune thrombocytopenia (R/R ITP), undergo the heavy burden of disease which decreases the quality of life. Lots of pathogeneses take part in the occurrence of R/R ITP, and the most important one of them is antibody-mediated immune platelet destruction. As far as it is known，human platelet autoantibodies are mainly secreted by plasma cells, especially long-lived plasma cells. Researchers want to explore that can BCMA CAR-T help R/R ITP patients increase platelet count, reduce bleeding episodes and the dose of concomitant medications. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05315778
Study type	Interventional
Source	The First Affiliated Hospital of Soochow University
Contact
Status	Recruiting
Phase	Phase 2
Start date	January 1, 2022
Completion date	June 30, 2023

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05281068` - The Combination of Iguratimod and Danazol as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia	Phase 2
Recruiting	`NCT05635266` - Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
Completed	`NCT02914054` - Therapy of Adults Affected by Idiopathic Thrombocytopenic Purpura With Dexamethasone	Phase 2/Phase 3
Recruiting	`NCT05116423` - Machine-learning Based Prediction Model in Primary Immune Thrombocytopenia
Terminated	`NCT04904276` - Observational Study of Fostamatinib as Second Line Therapy in Adult Patients With Immune Thrombocytopenia (ITP) and Insufficient Response to a Prior Therapy
Recruiting	`NCT04747080` - The Combination of Tacrolimus and High-dose Dexamethasone as First-line Treatment in Adult Immune Thrombocytopenia	Phase 2
Not yet recruiting	`NCT04482777` - IL37,Tlymphocytes,NK Cells in Pathogenesis of ITP
Recruiting	`NCT05446831` - Baricitinib for Steroid-resistant/Relapse Immune Thrombocytopenia	Phase 2
Active, not recruiting	`NCT04703621` - The DART Study- Daratumumab Treatment in ITP	Phase 2
Recruiting	`NCT05118126` - Gut Microbiota in ITP
Active, not recruiting	`NCT04943042` - An Observational, Multicenter Study to Evaluate the Use and Effectiveness of Doptelet® in Patients With ITP
Completed	`NCT04089267` - Evaluating the Efficacy and Safety of Different Human Thrombopoietin (rhTPO) Regimens in the Treatment of Patients With Primary Immune Thrombocytopenia (ITP)	Phase 4
Recruiting	`NCT04735588` - Investigation on the Incidence and Course of COVID-19 in Patients With Prior, Ongoing or de Novo ITP. Evaluation of the Impact of COVID-19 Pandemic on the Management of ITP